Neratinib - Latest Advances

68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging.

Journal: Bioorganic chemistry

Published: July 21, 2025

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.

Journal: bioRxiv : the preprint server for biology

Published: July 17, 2025

HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: July 07, 2025

Identification of Drug Repurposing Candidates for Coxsackievirus B3 Infection in iPSC-Derived Brain-like Endothelial Cells.

Journal: International journal of molecular sciences

Published: June 25, 2025

Increased Antiproliferative Activity of Antiestrogens and Neratinib Treatment by Calcitriol in HER2-Positive Breast Cancer Cells.

Journal: International journal of molecular sciences

Published: May 31, 2025

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Journal: Pharmacological research

Published: May 27, 2025

Blautia luti reduces neratinib-induced diarrhea in a rat model.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: May 19, 2025

Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer.

Journal: Scientific reports

Published: May 14, 2025

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Journal: Cancer chemotherapy and pharmacology

Published: May 14, 2025

Photosensitive smart hydrogel loaded Neratinib for NIR-triggered photodynamic treatment for improved chemotherapy in breast cancers- In vitro and In vivo analysis.

Journal: Journal of pharmaceutical sciences

Published: May 12, 2025

Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma.

Journal: Acta neuropathologica communications

Published: May 01, 2025

Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity.

Journal: Bioorganic chemistry

Published: April 29, 2025

Filters

68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging.

68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging.

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.

HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data.

HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data.

Identification of Drug Repurposing Candidates for Coxsackievirus B3 Infection in iPSC-Derived Brain-like Endothelial Cells.

Identification of Drug Repurposing Candidates for Coxsackievirus B3 Infection in iPSC-Derived Brain-like Endothelial Cells.

Increased Antiproliferative Activity of Antiestrogens and Neratinib Treatment by Calcitriol in HER2-Positive Breast Cancer Cells.

Increased Antiproliferative Activity of Antiestrogens and Neratinib Treatment by Calcitriol in HER2-Positive Breast Cancer Cells.

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update.

Blautia luti reduces neratinib-induced diarrhea in a rat model.

Blautia luti reduces neratinib-induced diarrhea in a rat model.

Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer.

Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer.

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Photosensitive smart hydrogel loaded Neratinib for NIR-triggered photodynamic treatment for improved chemotherapy in breast cancers- In vitro and In vivo analysis.

Photosensitive smart hydrogel loaded Neratinib for NIR-triggered photodynamic treatment for improved chemotherapy in breast cancers- In vitro and In vivo analysis.

Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma.

Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma.

Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity.

Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity.